Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis have?
Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis has 14 citations in the OpenAlex counts ScholarIQ stores.
When was Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis published?
Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis has 2021 year in the ScholarIQ index.
What is the open-access status of Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis?
Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis has gold oa status in the ScholarIQ index.
What is the DOI of Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis?
The DOI for Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis is on the source record.
What is the PMID of Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis?
The PMID for Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis is on the source record.
What is the OpenAlex record for Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis?
The OpenAlex for Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis is on the source record.